Jean-Claude Carel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Claude Carel has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Emmanuel Ecosse
AP-HP (E.E., J.C.), Hôtel Dieu, Biostatistics and Epidemiology Unit, F-75004 Paris, France
4 shared publicationsNajiba Lahlou
Laboratory of Hormonal Biochemistry
3 shared publicationsBéaTrice Faideau
Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 561, Groupe Hospitalier Cochin-Saint Vincent de Paul , Paris
2 shared publicationsCatherine Adamsbaum
Department of Radiology Groupe Hospitalier Cochin-Saint Vincent de Paul 75014 Paris France
2 shared publicationsChantal Lotton
Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 561, Groupe Hospitalier Cochin-Saint Vincent de Paul , Paris
2 shared publications- Christian Boitard
Inserm U1016, Institut Cochin, Paris, France
2 shared publications
Latest Publications
- 1 June 2015
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 172 (6) , 715-723
Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications
Objective: To assess in a pediatric population, the clinical characteristics and management of triiodothyronine-predominant Graves' disease (T3-P-GD), a rare condition well known in adults, but not previously described in children.Design: We conducted a university hospital-based observational study.Methods: All patients with GD followed for more than 1 year between 2003 and 2013 (n=60) were included. T3-P-GD (group I) was defined as high free T3 (fT3) concentration (>8.0 pmol/l) associated with a normal free thyroxine (fT4) concentration and undetectable TSH more than 1 month after the initiation of antithyroid drug (ATD) treatment. Group II contained patients with classical GD without T3-P-GD.Results: Eight (13%) of the patients were found to have T3-P-GD, a median of 6.3 (3.0–10.5) months after initial diagnosis (n=4) or 2.8 (2.0–11.9) months after the first relapse after treatment discontinuation (n=4). At GD diagnosis, group I patients were more likely to be younger (6.8 (4.3–11.0) vs 10.7 (7.2–13.7) years) and had more severe disease than group II patients, with higher serum TSH receptor autoantibodies (TRAb) levels: 40 (31–69) vs 17 (8–25) IU/l, P4 (92 (64–99) vs 63 (44–83) pmol/l) and fT3 (31 (30–46) vs 25 (17–31) pmol/l) concentrations. During the 3 years following T3-P-GD diagnosis, a double dose of ATD was required and median serum fT4:fT3 ratio remained lower in group I than in group II.Conclusion: Severe hyperthyroidism, with particularly high TRAb concentrations at diagnosis, may facilitate the identification of patients requiring regular serum fT3 determinations and potentially needing higher doses of ATD dosage during follow-up.
- 1 June 2015
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 172 (6) , 715-723
Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications
Objective: To assess in a pediatric population, the clinical characteristics and management of triiodothyronine-predominant Graves' disease (T3-P-GD), a rare condition well known in adults, but not previously described in children.Design: We conducted a university hospital-based observational study.Methods: All patients with GD followed for more than 1 year between 2003 and 2013 (n=60) were included. T3-P-GD (group I) was defined as high free T3 (fT3) concentration (>8.0 pmol/l) associated with a normal free thyroxine (fT4) concentration and undetectable TSH more than 1 month after the initiation of antithyroid drug (ATD) treatment. Group II contained patients with classical GD without T3-P-GD.Results: Eight (13%) of the patients were found to have T3-P-GD, a median of 6.3 (3.0–10.5) months after initial diagnosis (n=4) or 2.8 (2.0–11.9) months after the first relapse after treatment discontinuation (n=4). At GD diagnosis, group I patients were more likely to be younger (6.8 (4.3–11.0) vs 10.7 (7.2–13.7) years) and had more severe disease than group II patients, with higher serum TSH receptor autoantibodies (TRAb) levels: 40 (31–69) vs 17 (8–25) IU/l, P4 (92 (64–99) vs 63 (44–83) pmol/l) and fT3 (31 (30–46) vs 25 (17–31) pmol/l) concentrations. During the 3 years following T3-P-GD diagnosis, a double dose of ATD was required and median serum fT4:fT3 ratio remained lower in group I than in group II.Conclusion: Severe hyperthyroidism, with particularly high TRAb concentrations at diagnosis, may facilitate the identification of patients requiring regular serum fT3 determinations and potentially needing higher doses of ATD dosage during follow-up.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
High frequency of FGFR1 mutations in patients with congenital hypogonadotropic hypogonadism and split hand/foot malformation
Background: Congenital hypogonadotropic hypogonadism (CHH) is characterized by absent puberty and infertility due to a lack of GnRH secretion/action. In addition, patients exhibit variable non-reproductive phenotypes such as anosmia, cleft palate, synkinesia, and others. As many as 10% of CHH patients harbor mutations in FGFR1; this group is enriched for skeletal anomalies. We report here a novel CHH-associated skeletal phenotype, split hand/foot malformation (SHFM), defined as absent development of the central ray. Methods: CHH patients exhibiting SHFM were identified from four international CHH cohorts. Probands and available family members underwent extensive phenotyping and were screened for mutations in FGFR1. The functional impact of identified mutations was assessed by homology modelling, crystallography-based structural predictions, and/or in vitro assays. Results: We identified eight CHH probands exhibiting SHFM. Seven of these probands (88%) harbored FGFR1 mutations, including one homozygous (p.V429E) and six heterozygous mutations (p.G348R, p.G485R, p.Q594X, p.E670A, p.V688L, p.L712P). They all exhibited severe GnRH deficiency with absent puberty; cryptorchidism and/or micropenis were present in 5/7. Incomplete penetrance and variable expressivity of phenotypes (olfactory/reproductive/SHFM) were observed among mutation carriers in each family. All mutations were predicted to be loss-of-function by homology and structural modelling. The V429E mutation maps to the FRS2 binding domain of FGFR1; functional studies demonstrated that it decreases recruitment and association of FRS2Θ to FGFR1, thereby resulting in reduced MAPK signalling. Conclusion: SHFM is a novel CHH-associated phenotype. Mice with limb mesenchyme-specific knock-out of Fgfr1 exhibit absent central ray development, thus phenocopying SHFM. FGFR1 should be prioritized for sequencing in CHH patients with SHFM, because the likelihood of finding a mutation increases from 10% (general CHH population) to 88% (CHH+SHFM).
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
High frequency of FGFR1 mutations in patients with congenital hypogonadotropic hypogonadism and split hand/foot malformation
Background: Congenital hypogonadotropic hypogonadism (CHH) is characterized by absent puberty and infertility due to a lack of GnRH secretion/action. In addition, patients exhibit variable non-reproductive phenotypes such as anosmia, cleft palate, synkinesia, and others. As many as 10% of CHH patients harbor mutations in FGFR1; this group is enriched for skeletal anomalies. We report here a novel CHH-associated skeletal phenotype, split hand/foot malformation (SHFM), defined as absent development of the central ray. Methods: CHH patients exhibiting SHFM were identified from four international CHH cohorts. Probands and available family members underwent extensive phenotyping and were screened for mutations in FGFR1. The functional impact of identified mutations was assessed by homology modelling, crystallography-based structural predictions, and/or in vitro assays. Results: We identified eight CHH probands exhibiting SHFM. Seven of these probands (88%) harbored FGFR1 mutations, including one homozygous (p.V429E) and six heterozygous mutations (p.G348R, p.G485R, p.Q594X, p.E670A, p.V688L, p.L712P). They all exhibited severe GnRH deficiency with absent puberty; cryptorchidism and/or micropenis were present in 5/7. Incomplete penetrance and variable expressivity of phenotypes (olfactory/reproductive/SHFM) were observed among mutation carriers in each family. All mutations were predicted to be loss-of-function by homology and structural modelling. The V429E mutation maps to the FRS2 binding domain of FGFR1; functional studies demonstrated that it decreases recruitment and association of FRS2Θ to FGFR1, thereby resulting in reduced MAPK signalling. Conclusion: SHFM is a novel CHH-associated phenotype. Mice with limb mesenchyme-specific knock-out of Fgfr1 exhibit absent central ray development, thus phenocopying SHFM. FGFR1 should be prioritized for sequencing in CHH patients with SHFM, because the likelihood of finding a mutation increases from 10% (general CHH population) to 88% (CHH+SHFM).
- 1 July 2012
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (7) , E1241-E1248
Parental Origin of the X-Chromosome Does Not Influence Growth Hormone Treatment Effect in Turner Syndrome
Context: The parental origin of the intact X-chromosome has been reported to affect phenotype and response to GH treatment in Turner syndrome (TS). Objective: Our objective was to evaluate the influence of the parental origin of the X-chromosome on body growth and GH treatment effect in TS. Design and Setting: We conducted a population-based cohort study of TS patients previously treated with GH. Participants: Participants included patients with a nonmosaic 45,X karyotype; 556 women were identified as eligible, 233 (49%) of whom participated, together with their mothers. Data were analyzed for 180 of these patients. Main Outcome Measures: We performed fluorescence in situ hybridization analysis to exclude mosaicism and microsatellite analysis of nine polymorphic markers in DNA from the patients and their mothers. The influence on growth and effect of GH were analyzed by univariate and multivariate methods. Results: The X-chromosome was of paternal origin (Xpat) in 52 (29%) of 180 and of maternal origin (Xmat) in 128 (71%) of 180 patients. Height gain from the start of GH treatment to adult height was similar in Xmat and Xpat patients (+2.1 ± 0.9 vs. +2.2 ± 0.8 TS sd score, P = 0.45). The lack of influence of parental origin of the X-chromosome was confirmed in multivariate analysis. Parental origin of the X-chromosome also had no effect on the other growth characteristics studied, including growth velocity during the first year on GH treatment. Patient height was correlated with the heights of both parents and was not influenced by the parental origin of the X-chromosome. Conclusion: In this, the largest such study carried out to date, the parental origin of the X-chromosome did not alter the effect of GH treatment or affect any other features of growth in TS.
- 1 July 2012
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (7) , E1241-E1248
Parental Origin of the X-Chromosome Does Not Influence Growth Hormone Treatment Effect in Turner Syndrome
Context: The parental origin of the intact X-chromosome has been reported to affect phenotype and response to GH treatment in Turner syndrome (TS). Objective: Our objective was to evaluate the influence of the parental origin of the X-chromosome on body growth and GH treatment effect in TS. Design and Setting: We conducted a population-based cohort study of TS patients previously treated with GH. Participants: Participants included patients with a nonmosaic 45,X karyotype; 556 women were identified as eligible, 233 (49%) of whom participated, together with their mothers. Data were analyzed for 180 of these patients. Main Outcome Measures: We performed fluorescence in situ hybridization analysis to exclude mosaicism and microsatellite analysis of nine polymorphic markers in DNA from the patients and their mothers. The influence on growth and effect of GH were analyzed by univariate and multivariate methods. Results: The X-chromosome was of paternal origin (Xpat) in 52 (29%) of 180 and of maternal origin (Xmat) in 128 (71%) of 180 patients. Height gain from the start of GH treatment to adult height was similar in Xmat and Xpat patients (+2.1 ± 0.9 vs. +2.2 ± 0.8 TS sd score, P = 0.45). The lack of influence of parental origin of the X-chromosome was confirmed in multivariate analysis. Parental origin of the X-chromosome also had no effect on the other growth characteristics studied, including growth velocity during the first year on GH treatment. Patient height was correlated with the heights of both parents and was not influenced by the parental origin of the X-chromosome. Conclusion: In this, the largest such study carried out to date, the parental origin of the X-chromosome did not alter the effect of GH treatment or affect any other features of growth in TS.
- 1 June 2011
- Published by The Endocrine Society
- p. LB-5
Long-Term Mortality after Recombinant Growth Hormone Treatment for Isolated Childhood Short Stature: Report of the French SAGhE Study
Recombinant growth hormone treatment is widely used to promote growth in children with short stature. Little is known about the long-term safety of such treatment. SAGhE (safety and appropriateness of growth hormone treatments in Europe) is a large study evaluating the long-term health of individuals treated with recombinant growth hormone in childhood in eight European countries. We report on the mortality results of the study performed in France where it was initiated before the rest of Europe. This population-based cohort study was based on the French population-based register of children treated with growth hormone. 6928 short children diagnosed with idiopathic isolated growth hormone deficiency, idiopathic short stature or born short for gestational age who started recombinant growth hormone treatment between 1985 and 1996. Follow-up data on vital status were available in September 2009 for 94.7% of the patients, providing 116,403 person-years of observation. We measured all-cause and cause-specific mortality and calculated standardised mortality ratios (SMR) and hazard ratios (HR, using the category with the lowest exposure level as the reference). All-cause mortality was higher in treated children than in the general population (SMR 1.33. 95% CI 1.08–1.64). In multivariate analysis adjusted for height at the start of treatment, the use of high doses typically exceeding 50 µg/kg/day was consistently associated with mortality rates almost three times those for the low-dose regimen, using both external and internal references (adjusted SMR 2.94, 95% CI 1.22–7.07, adjusted HR 2.79, 95% CI 1.14–6.82). Cancer-related mortality was not higher than for the general population, although bone tumour-related mortality was five times higher (SMR 5.00, 95% CI 1.01–14.63). An increase in mortality due to diseases of the circulatory system (SMR 3.07, 95% CI 1.40–5.83), and subarachnoid or intracerebral haemorrhage in particular (SMR 6.66, 95% CI 1.79–17.05), was also observed. In conclusion, mortality rates were significantly increased in this population of otherwise healthy but short children treated with recombinant growth hormone, particularly in those who had received the highest doses. Specific effects were detected in terms of death due to bone tumours or cerebral haemorrhage, but not for all cancers. These results highlight the need for additional studies of long-term mortality and morbidity after growth hormone treatment in childhood. Sources of Research Support: The study was funded by Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS, the French drug safety agency), Direction Generale de la Sante (DGS, French Ministry of Health), Institut National du Cancer (INCa) and a Commission of European Communities grant (HEALTH-F2-2009-223497). J-CC: Investigator, Lilly USA, LLC; Scientific Board Member, Pfizer Global R&D. Nothing to Disclose: EE, FL, DM-H, FK, GR, JC
- 1 June 2011
- Published by The Endocrine Society
- p. LB-5
Long-Term Mortality after Recombinant Growth Hormone Treatment for Isolated Childhood Short Stature: Report of the French SAGhE Study
Recombinant growth hormone treatment is widely used to promote growth in children with short stature. Little is known about the long-term safety of such treatment. SAGhE (safety and appropriateness of growth hormone treatments in Europe) is a large study evaluating the long-term health of individuals treated with recombinant growth hormone in childhood in eight European countries. We report on the mortality results of the study performed in France where it was initiated before the rest of Europe. This population-based cohort study was based on the French population-based register of children treated with growth hormone. 6928 short children diagnosed with idiopathic isolated growth hormone deficiency, idiopathic short stature or born short for gestational age who started recombinant growth hormone treatment between 1985 and 1996. Follow-up data on vital status were available in September 2009 for 94.7% of the patients, providing 116,403 person-years of observation. We measured all-cause and cause-specific mortality and calculated standardised mortality ratios (SMR) and hazard ratios (HR, using the category with the lowest exposure level as the reference). All-cause mortality was higher in treated children than in the general population (SMR 1.33. 95% CI 1.08–1.64). In multivariate analysis adjusted for height at the start of treatment, the use of high doses typically exceeding 50 µg/kg/day was consistently associated with mortality rates almost three times those for the low-dose regimen, using both external and internal references (adjusted SMR 2.94, 95% CI 1.22–7.07, adjusted HR 2.79, 95% CI 1.14–6.82). Cancer-related mortality was not higher than for the general population, although bone tumour-related mortality was five times higher (SMR 5.00, 95% CI 1.01–14.63). An increase in mortality due to diseases of the circulatory system (SMR 3.07, 95% CI 1.40–5.83), and subarachnoid or intracerebral haemorrhage in particular (SMR 6.66, 95% CI 1.79–17.05), was also observed. In conclusion, mortality rates were significantly increased in this population of otherwise healthy but short children treated with recombinant growth hormone, particularly in those who had received the highest doses. Specific effects were detected in terms of death due to bone tumours or cerebral haemorrhage, but not for all cancers. These results highlight the need for additional studies of long-term mortality and morbidity after growth hormone treatment in childhood. Sources of Research Support: The study was funded by Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS, the French drug safety agency), Direction Generale de la Sante (DGS, French Ministry of Health), Institut National du Cancer (INCa) and a Commission of European Communities grant (HEALTH-F2-2009-223497). J-CC: Investigator, Lilly USA, LLC; Scientific Board Member, Pfizer Global R&D. Nothing to Disclose: EE, FL, DM-H, FK, GR, JC
- Open Access
- 1 August 2006
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 91 (8) , 2972-2979
Self-Esteem and Social Adjustment in Young Women with Turner Syndrome—Influence of Pubertal Management and Sexuality: Population-Based Cohort Study
Context: Pediatric management of patients with Turner syndrome focuses on height, frequently resulting in a delay of pubertal induction. The influence of pubertal management on psychosocial adjustment and sex life has not been evaluated in Turner syndrome patients. Objective: The objective of the study was to identify the determinants of self-esteem, social adjustment, and initiation of sex life in patients with Turner syndrome, particularly those related to pubertal management. Design: This was a prospective evaluation, the StaTur study. Setting: The study was conducted with a population-based registry of GH-treated patients. Participants: Participants included 566 young adult women with Turner syndrome, aged 22.6 ± 2.6 yr (range, 18.3–31.2). Main Outcome Measures: Measures used in the study were Coopersmith’s Self-Esteem Inventory, Social Adjustment Scale Self-Report, questions on sexual experience, and extensive data on pediatric management. Results: Low self-esteem was associated with otological involvement and limited sexual experience. Low social adjustment was associated with lower paternal socioeconomic class and an absence of sexual experience. Late age at first kiss or date was associated with cardiac involvement and a lack of spontaneous pubertal development. Age at first sexual intercourse was related to age at puberty and paternal socioeconomic class. Delayed induction of puberty had a long-lasting effect on sex life. Height and height gain due to GH treatment had no effect on outcomes. Conclusions: Puberty should be induced at a physiologically appropriate age in patients with Turner syndrome to optimize self-esteem, social adjustment, and initiation of the patient’s sex life. Therapeutic interventions altering normal pubertal development in other groups of patients should be reconsidered in light of these findings.
- 1 August 2006
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 91 (8) , 2972-2979
Open AccessSelf-Esteem and Social Adjustment in Young Women with Turner Syndrome—Influence of Pubertal Management and Sexuality: Population-Based Cohort Study
Context: Pediatric management of patients with Turner syndrome focuses on height, frequently resulting in a delay of pubertal induction. The influence of pubertal management on psychosocial adjustment and sex life has not been evaluated in Turner syndrome patients. Objective: The objective of the study was to identify the determinants of self-esteem, social adjustment, and initiation of sex life in patients with Turner syndrome, particularly those related to pubertal management. Design: This was a prospective evaluation, the StaTur study. Setting: The study was conducted with a population-based registry of GH-treated patients. Participants: Participants included 566 young adult women with Turner syndrome, aged 22.6 ± 2.6 yr (range, 18.3–31.2). Main Outcome Measures: Measures used in the study were Coopersmith’s Self-Esteem Inventory, Social Adjustment Scale Self-Report, questions on sexual experience, and extensive data on pediatric management. Results: Low self-esteem was associated with otological involvement and limited sexual experience. Low social adjustment was associated with lower paternal socioeconomic class and an absence of sexual experience. Late age at first kiss or date was associated with cardiac involvement and a lack of spontaneous pubertal development. Age at first sexual intercourse was related to age at puberty and paternal socioeconomic class. Delayed induction of puberty had a long-lasting effect on sex life. Height and height gain due to GH treatment had no effect on outcomes. Conclusions: Puberty should be induced at a physiologically appropriate age in patients with Turner syndrome to optimize self-esteem, social adjustment, and initiation of the patient’s sex life. Therapeutic interventions altering normal pubertal development in other groups of patients should be reconsidered in light of these findings.
- Open Access
- 1 July 2006
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 177 (1) , 53-60
Tolerance to Proinsulin-2 Is Due to Radioresistant Thymic Cells
Proinsulin is a key Ag in type 1 diabetes, but the mechanisms regulating proinsulin immune tolerance are unknown. We have shown that preproinsulin-2 gene-deficient mice (proins-2−/−) are intolerant to proinsulin-2. In this study, we analyzed the mechanisms underlying T cell-mediated tolerance to proinsulin-2 in 129/Sv nonautoimmune mice. The expression of one proinsulin-2 allele, whatever its parental origin, was sufficient to maintain tolerance. The site of proinsulin-2 expression relevant to tolerance was evaluated in thymus and bone marrow chimeras. CD4+ T cell reactivity to proinsulin-2 was independent of proinsulin-2 expression in radiation-sensitive bone marrow-derived cells. A wt thymus restored tolerance in proins-2−/− mice. Conversely, the absence of the preproinsulin-2 gene in radioresistant thymic cells was sufficient to break tolerance. Although chimeric animals had proinsulin-2-reactive CD4+ T cells in their peripheral repertoire, they displayed no insulitis or insulin Abs, suggesting additional protective mechanisms. In a model involving transfer to immunodeficient (CD3ε−/−) mice, naive and proinsulin-2-primed CD4+ T cells were not activated, but could be activated by immunization regardless of whether the recipient mice expressed proinsulin-2. Furthermore, we could not identify a role for putative specific T cells regulating proinsulin-2-reactive CD4+ T in transfer experiments. Thus, proinsulin-2 gene expression by radioresistant thymic epithelial cells is involved in the induction of self-tolerance, and additional factors are required to induce islet abnormalities.
- 1 July 2006
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 177 (1) , 53-60
Open AccessTolerance to Proinsulin-2 Is Due to Radioresistant Thymic Cells
Proinsulin is a key Ag in type 1 diabetes, but the mechanisms regulating proinsulin immune tolerance are unknown. We have shown that preproinsulin-2 gene-deficient mice (proins-2−/−) are intolerant to proinsulin-2. In this study, we analyzed the mechanisms underlying T cell-mediated tolerance to proinsulin-2 in 129/Sv nonautoimmune mice. The expression of one proinsulin-2 allele, whatever its parental origin, was sufficient to maintain tolerance. The site of proinsulin-2 expression relevant to tolerance was evaluated in thymus and bone marrow chimeras. CD4+ T cell reactivity to proinsulin-2 was independent of proinsulin-2 expression in radiation-sensitive bone marrow-derived cells. A wt thymus restored tolerance in proins-2−/− mice. Conversely, the absence of the preproinsulin-2 gene in radioresistant thymic cells was sufficient to break tolerance. Although chimeric animals had proinsulin-2-reactive CD4+ T cells in their peripheral repertoire, they displayed no insulitis or insulin Abs, suggesting additional protective mechanisms. In a model involving transfer to immunodeficient (CD3ε−/−) mice, naive and proinsulin-2-primed CD4+ T cells were not activated, but could be activated by immunization regardless of whether the recipient mice expressed proinsulin-2. Furthermore, we could not identify a role for putative specific T cells regulating proinsulin-2-reactive CD4+ T in transfer experiments. Thus, proinsulin-2 gene expression by radioresistant thymic epithelial cells is involved in the induction of self-tolerance, and additional factors are required to induce islet abnormalities.
- 1 July 2006
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 254-255, 226-233
Management of short stature with GnRH agonist and co-treatment with growth hormone: A controversial issue
- 1 July 2006
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 254-255, 226-233
Management of short stature with GnRH agonist and co-treatment with growth hormone: A controversial issue
- Open Access
- 1 February 2006
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 154 (2) , 221-227
Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor
Background: Peutz-Jeghers syndrome (PJS) is a rare autosomal-dominant disorder characterized by multiple gastrointestinal hamartomatous polyps, mucocutaneous pigmentation and increased predisposition to various neoplasms. Endocrine manifestations in PJS include gynecomastia due to calcified Sertoli cell testicular tumors usually referred to as large-cell calcifying Sertoli cell tumors (LSCT). Objective: To evaluate the value of endocrine markers and aromatase inhibitor treatment in children with PJS and LSCT. Design and setting: Familial cases, followed in a tertiary care center. Patients: Two male siblings aged 7 and 9 years with PJS and LSCT. Intervention: Third generation aromatase inhibitor (anastrozole) in one of the patients. Main outcome measures: Longitudinal measurements of sex-steroids, gonadotropins, Sertoli cell markers and auxological evaluation. Results: The two male siblings with PJS had similar bilateral multifocal testicular calcifications and biochemical evidence of Sertoli cell dysfunction manifested by elevated plasma inhibin-α levels. Only one sibling had gynecomastia. Estradiol levels were normal in both. During treatment with anastrozole, estradiol levels, growth and skeletal maturation, as well as Sertoli cell markers (inhibin B, inhibin-α and anti-Mullerian hormone) decreased. Conclusions: Inhibin-α may be considered as a marker for LSCT in children with PJS, pointing to a specific defect in inhibin regulation in this condition. Moreover, the decrease in Sertoli cell markers during aromatase inhibitor treatment suggests that increased estrogen production is a primary event regulating downstream production of Sertoli cell peptides. Anastrozole is efficient in controlling the clinical features of the disease and should be proposed as an alternative to bilateral orchidectomy, which is often performed in this condition.
- 1 February 2006
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 154 (2) , 221-227
Open AccessPrepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor
Background: Peutz-Jeghers syndrome (PJS) is a rare autosomal-dominant disorder characterized by multiple gastrointestinal hamartomatous polyps, mucocutaneous pigmentation and increased predisposition to various neoplasms. Endocrine manifestations in PJS include gynecomastia due to calcified Sertoli cell testicular tumors usually referred to as large-cell calcifying Sertoli cell tumors (LSCT). Objective: To evaluate the value of endocrine markers and aromatase inhibitor treatment in children with PJS and LSCT. Design and setting: Familial cases, followed in a tertiary care center. Patients: Two male siblings aged 7 and 9 years with PJS and LSCT. Intervention: Third generation aromatase inhibitor (anastrozole) in one of the patients. Main outcome measures: Longitudinal measurements of sex-steroids, gonadotropins, Sertoli cell markers and auxological evaluation. Results: The two male siblings with PJS had similar bilateral multifocal testicular calcifications and biochemical evidence of Sertoli cell dysfunction manifested by elevated plasma inhibin-α levels. Only one sibling had gynecomastia. Estradiol levels were normal in both. During treatment with anastrozole, estradiol levels, growth and skeletal maturation, as well as Sertoli cell markers (inhibin B, inhibin-α and anti-Mullerian hormone) decreased. Conclusions: Inhibin-α may be considered as a marker for LSCT in children with PJS, pointing to a specific defect in inhibin regulation in this condition. Moreover, the decrease in Sertoli cell markers during aromatase inhibitor treatment suggests that increased estrogen production is a primary event regulating downstream production of Sertoli cell peptides. Anastrozole is efficient in controlling the clinical features of the disease and should be proposed as an alternative to bilateral orchidectomy, which is often performed in this condition.
- 1 January 2006
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 154 (1) , 119-124
Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty
Objective: Depot GnRH agonists are commonly used in the treatment of central precocious puberty (CPP). The triptorelin 11.25 mg 3-month depot, currently used in adult indications, had not previously been evaluated in CPP. Design: This was a multicenter, open-label, 12 month trial conducted in 64 CPP children (54 girls and 10 boys), treated quarterly. Methods: Children with a clinical onset of pubertal development before the age of 8 years (girls) or 9 years (boys), pubertal response of LH to GnRH ≥7 IU/l, advanced bone age >1 year, enlarged uterus (≥36 mm) and testosterone level ≥0.5 ng/ml (boys), were included. Suppression of gonadotropic activation, as determined from serum LH, FSH, estradiol or testosterone, and pubertal signs were assessed at Months 3, 6 and 12. Results: GnRH-stimulated peak LH ≤3 IU/l, the main efficacy criterion, was met in 53 out of 62 (85%), 60 out of 62 (97%) and 56 out of 59 (95%) of the children at Months 3, 6 and 12 respectively. Serum FSH and sex steroids were also significantly reduced, while pubertal development regressed in most patients. Mean residual triptorelin levels were stable from Month 3 through to Month 12. The triptorelin 3-month depot was well tolerated. Severe injection pain was experienced in only one instance. Five girls experienced mild-to-moderate or severe (one girl) withdrawal bleeding. Conclusions: The triptorelin 3-month depot efficiently suppresses the pituitary–gonadal axis and pubertal development in children with CPP. This formulation allows a 3-fold reduction, over the once-a-month depot, in the number of i.m. injections required each year.
- 1 January 2006
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 154 (1) , 119-124
Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty
Objective: Depot GnRH agonists are commonly used in the treatment of central precocious puberty (CPP). The triptorelin 11.25 mg 3-month depot, currently used in adult indications, had not previously been evaluated in CPP. Design: This was a multicenter, open-label, 12 month trial conducted in 64 CPP children (54 girls and 10 boys), treated quarterly. Methods: Children with a clinical onset of pubertal development before the age of 8 years (girls) or 9 years (boys), pubertal response of LH to GnRH ≥7 IU/l, advanced bone age >1 year, enlarged uterus (≥36 mm) and testosterone level ≥0.5 ng/ml (boys), were included. Suppression of gonadotropic activation, as determined from serum LH, FSH, estradiol or testosterone, and pubertal signs were assessed at Months 3, 6 and 12. Results: GnRH-stimulated peak LH ≤3 IU/l, the main efficacy criterion, was met in 53 out of 62 (85%), 60 out of 62 (97%) and 56 out of 59 (95%) of the children at Months 3, 6 and 12 respectively. Serum FSH and sex steroids were also significantly reduced, while pubertal development regressed in most patients. Mean residual triptorelin levels were stable from Month 3 through to Month 12. The triptorelin 3-month depot was well tolerated. Severe injection pain was experienced in only one instance. Five girls experienced mild-to-moderate or severe (one girl) withdrawal bleeding. Conclusions: The triptorelin 3-month depot efficiently suppresses the pituitary–gonadal axis and pubertal development in children with CPP. This formulation allows a 3-fold reduction, over the once-a-month depot, in the number of i.m. injections required each year.
- 1 April 2005
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (4) , 1992-1997
Quality of Life Determinants in Young Women with Turner’s Syndrome after Growth Hormone Treatment: Results of the StaTur Population-Based Cohort Study
GH is used to increase adult height in children with Turner's syndrome with little knowledge of the impact on quality of life. We carried out a population-based cohort study of quality-of-life determinants in young women with Turner's syndrome, all previously treated with GH. Of 891 eligible women aged over 18 yr and recorded in the French Growth Hormone Register, 818 were available and 568 participated (69%). They were assessed for demographic characteristics, health status, sexual life, treatment expectations, scores for Medical Outcome Study Short Form 36 (SF-36), and General Health Questionnaire 12. Participants were 22.6 +/- 2.6 yr old (mean +/- sd), measured 150.9 +/- 5.6 cm, and had received GH for 4.8 +/- 2.2 yr. SF-36 scores were similar in participants and French women of the general population. Cardiac (12% of participants) or otological (26% of participants) involvement or induction of puberty after 15 yr of age was associated with lower scores for at least one of the SF-36 dimensions. Height and estimated height gain from treatment were not associated with quality-of-life scores. Higher expectations from treatment were associated with lower quality of life. We conclude that quality of life is normal and unaffected by height in young adults with Turner's syndrome treated with GH. These data emphasize the need to give appropriate attention to general health and otological care rather than focus on stature in the care of children with Turner's syndrome.
- 1 April 2005
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (4) , 1992-1997
Quality of Life Determinants in Young Women with Turner’s Syndrome after Growth Hormone Treatment: Results of the StaTur Population-Based Cohort Study
GH is used to increase adult height in children with Turner's syndrome with little knowledge of the impact on quality of life. We carried out a population-based cohort study of quality-of-life determinants in young women with Turner's syndrome, all previously treated with GH. Of 891 eligible women aged over 18 yr and recorded in the French Growth Hormone Register, 818 were available and 568 participated (69%). They were assessed for demographic characteristics, health status, sexual life, treatment expectations, scores for Medical Outcome Study Short Form 36 (SF-36), and General Health Questionnaire 12. Participants were 22.6 +/- 2.6 yr old (mean +/- sd), measured 150.9 +/- 5.6 cm, and had received GH for 4.8 +/- 2.2 yr. SF-36 scores were similar in participants and French women of the general population. Cardiac (12% of participants) or otological (26% of participants) involvement or induction of puberty after 15 yr of age was associated with lower scores for at least one of the SF-36 dimensions. Height and estimated height gain from treatment were not associated with quality-of-life scores. Higher expectations from treatment were associated with lower quality of life. We conclude that quality of life is normal and unaffected by height in young adults with Turner's syndrome treated with GH. These data emphasize the need to give appropriate attention to general health and otological care rather than focus on stature in the care of children with Turner's syndrome.